LidoSite®
(Lidocaine HCl/Epinephrine Topical Iontophoretic Patch) 10%/0.1%

If you are afraid of the pain of needles, take a little heart.

Now needles don't have to hurt with LidoSite.

In just 10 minutes, LidoSite, the first FDA-approved pre-filled active anesthetic patch, delivers a trusted anesthetic deep into the skin to reduce the pain of needles. You can take heart that needle pain can be a thing of the past.

According to a recent survey, up to 40 million Americans associate high levels of pain with needles. This fear can turn routine doctor visits and testing procedures into stressful or even traumatic experiences, and can lead to the avoidance of blood draws and other medical interventions, resulting in suboptimal medical care. In fact, a study of more than 11,000 patients who had blood drawn within the last six months showed:

- As many as 14% of adults and 36% of children associate high levels of pain with needles and blood draws.[1]
- 23% of these adults had gone so far as to refuse a blood draw because of the fear of needle pain.[1]

The LidoSite topical system is indicated for use on normal, intact skin to provide local analgesia for superficial dermatological procedures such as venipuncture, IV cannulation, and laser ablation of superficial skin lesions. The LidoSite system is indicated for use on patients 5 years of age and older.

LidoSite is a prescription only product.

To find out more, ask your nurse, call 888-VYTERIS (898-3747), or visit us online at:
www.vyteris.com/lidosite

vyteris

Vyteris, Inc. (OTCBB:VYHN.OB), is the maker of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris' proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy.

This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration.

Vyteris' lead product, LidoSite®, which provides dermal analgesia prior to venipuncture (IV catheter insertions, blood draws, etc.) and superficial dermatological procedures, was the first FDA-approved active patch. Vyteris has entered into several agreements to market LidoSite and develop new products from its transdermal technology.

LidoSite®

(Lidocaine HCl/Epinephrine Topical Iontophoretic Patch) 10%/0.1%

Important Safety Information

This material is provided for general information purposes only; it is not intended as a substitute for medical advice and/or consultation with an appropriate physician or technical expert. The LidoSite topical system is indicated for use on normal, intact skin to provide local analgesia for superficial dermatological procedures such as venipuncture, IV cannulation, and laser ablation of superficial skin lesions. The LidoSite system is indicated for use on patients 5 years of age and older.

The LidoSite system is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type, sulfites, or to any other component of the product. It is also contraindicated for use in patients with electrically-sensitive devices (e.g., pacemakers) and should not be used on areas of the body supplied by end arteries or having otherwise compromised blood supply.

Iontophoresis with the LidoSite patch may cause local, transient skin irritation such as blanching or erythema in the dermis under the patch. Patients over 65 years of age may have greater sensitivity to the LidoSite patch than younger patients. The potential exists for a small child to suffer serious adverse effects from chewing or ingesting a new or used LidoSite patch. Children should be closely observed when treated with the LidoSite system, and LidoSite patches should be stored and disposed of in the proper manner.

Please refer to the full prescribing information, including the detailed instructions for use, before using the LidoSite topical system.

1. TVG Study. Data on file, Vyteris, Inc. 2. WT Zempsky, et al. Evaluation of a Low-Dose Lidocaine Iontophoresis System for Topical Anesthesia in Adults and Children: A Randomized, Controlled Trial. *Clinical Therapeutics.* 2004; 26:1110-1119.

This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “would,” “should,” “believes,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this presentation include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this presentation. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption “Risk Factors” in its most recent Quarterly Report on Form 10-QSB and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this presentation.